Recent Updates
Recently added Catalysts

LAM-001

Phase 2

Bronchiolitis Obliterans Syndrome | Small molecule | Respiratory |IRulya Therapeutics Inc. Common Stock|Trials Updated: May 18, 2026

LAM-001 development status

Highest phase Phase 2
Registered trials 2 across 2 sponsors since Apr 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

LAM-001 clinical trials

LAM-001 · 1 trial · 3 indications

Phase 2 1
NCT06018766LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.Bronchiolitis Obliterans Syndrome
RECRUITING30 Analytics
PHASE2RECRUITING
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Bronchiolitis Obliterans Syndrome
NCT0601876630
Unlock trial analytics

Study Endpoints

Primary Endpoints

% change in FEV1 from baseline
48 week

Patient's % change in FEV1 from baseline at 48 weeks or termination of treatment, whichever is earlier

Secondary Endpoints

Absolute change in FEV1
48 weeks
Change in the rate of progression in FEV1
48 weeks
Time to Progression Free Survival (PFS), Level 1
48 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LAM-001EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
LAM-001DRUGLAM-001 administered via dry powder inhaler
PlaceboDRUGPlacebo administered via dry powder inhaler
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age \> 18 years old * Recipient of a double pulmonary allograft at least 12 months before study entry * Subjects with clinically diagnosed CLAD-BOS phenotype (all 3 required) * BOS defined as screening FEV1 between 85-51% of the baseline as defined by the 2 highest FEV1 mea...

Countries:United States
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

IRulya Therapeutics Inc. Common Stock (IRLA)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track